Skip to main content
. 2024 Oct 15;112(4 Suppl):10–16. doi: 10.4269/ajtmh.23-0802

Table 1.

Factors associated with acceptance of SARS-CoV-2 Ag-RDT

Characteristics Accepted Testing
n (%)
N = 1,006
Refused Testing
n (%)
N = 858
Unadjusted Analysis
OR (95% CI)
P-Value Adjusted Analysis
aOR (95% CI)
P-Value
Age
 Median (IQR) 35 (26–47) 32 (25–41) – <0.0001 – <0.0001
 ≤24 Years 189 (18.8) 183 (21.3) 0.49 (0.36–0.66) 0.51 (0.37–0.70)
 25–49 Years 602 (59.8) 574 (66.9) 0.49 (0.38–0.64) 0.51 (0.39–0.66)
 ≥50 Years 215 (21.4) 101 (11.8) Ref Ref
Sex, n (%)
 Male 640 (63.6) 499 (58.2) 1.26 (1.04–1.52) 0.016 1.26 (1.04–1.53) 0.017
 Female 366 (36.4) 359 (41.8) Ref Ref
Testing Point
 Mass Gathering Event 204 (20.3) 135 (15.7) 1.36 (1.07–1.73) 0.011 1.40 (1.08–1.82) 0.010
 Community Gathering Points 802 (79.7) 723 (84.3) Ref Ref
Region
 Center 475 (47.2) 487 (56.8) 0.68 (0.57–0.82) <0.0001 0.65 (0.54–0.79) <0.0001
 Littoral 531 (52.8) 371 (43.2) Ref Ref
Presence of Symptoms
 At Least One 122 (12.1) 60 (7.0) 1.80 (1.31–2.49) 0.0003 1.80 (1.30–2.50) 0.0005
 None 884 (87.9) 798 (93.1) Ref Ref
COVID Vaccine Status
 Fully Vaccinated 171 (17.0) 112 (13.1) Ref 0.018 Ref 0.044
 Not/Partially Vaccinated 835 (83.0) 746 (86.9) 0.73 (0.57–0.95) 0.76 (0.58–0.99)
Attendance and Mask Wearing at a Recent MGE
 Consistently 66 (6.6) 59 (6.7) 0.98 (0.67–1.41) 0.29 0.84 (0.58–1.24) 0.810
 Partially 71 (7.1) 42 (4.9) 1.47 (0.99–2.20) 1.20 (0.79–1.81)
 Never 294 (29.2) 256 (29.8) 1.00 (0.81–1.23) 0.95 (0.76–1.18)
 Did Not Attend MGE 575 (57.2) 501 (58.4) Ref Ref
Comorbidity
 At Least One 75 (7.5) 46 (5.4) Ref 0.067 – –
 None 929 (92.5) 812 (94.6) 1.42 (0.97–2.08) – –
 Missing 2 0 – – –
History of COVID-19 Disease
 Previous Infection 44 (4.4) 38 (4.4) 0.98 (0.63–1.53) 0.954 – –
 No Previous Infection 962 (95.6) 820 (95.6) Ref – –

Ag-RDT = antigen rapid diagnostic testing; aOR = adjusted odds ratio; COVID-19 = coronavirus disease-2019; IQR = interquartile range; MGE = mass gathering event; OR = odds ratio; Ref = reference; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2